TNFRSF25 and cancer: Since its apoptosis-inducing receptors DR4 and DR5 are rarely expressed on healthy cells but frequently overexpressed on cancer cells, TRAIL-based therapies may be highly effective against cancer cells while sparing healthy cells [53].